AbbVie Inc.
corporate_fare Company Profile
AbbVie Inc. (NYSE:ABBV) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 64 items for ABBV at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-23, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for ABBV spans 8-K, FWP, 424B5.
Recent high-impact activity:
- FDA Clears At-Home Subcutaneous Induction for Skyrizi in Crohn's Disease
- AbbVie's Lutikizumab Hits Late-Stage Endpoints in Hidradenitis Suppurativa
- Skyrizi Hits 36% Endoscopic Remission in Crohn's Phase 3, FDA Review Underway
- FDA Grants Two Breakthrough Therapy Designations to AbbVie's Temab-A
- AbbVie-Genmab Combo Cuts DLBCL Progression Risk by 51% in Phase 3
Financial Snapshot
Short Interest & Short Volume
2.72 days to coverFINRA reported short interest of 15,582,821 shares in ABBV as of the October 15, 2026 settlement, a 4.3% decrease from the prior period — about 2.7 days to cover at its recent average daily volume. On October 27, 2026, 34.2% of ABBV volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ABBV, detected from its recent SEC filings · based on capital-structure filings through 2026-08-06.
Bond Offering Finalized · Proceeds to Fund Apogee Acquisition
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →